ArticleOncoimmunology

Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.

Niannian Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.